Fresh Tracks Therapeutics Past Earnings Performance
Past criteria checks 0/6
Fresh Tracks Therapeutics's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 12.8% per year.
Key information
-5.8%
Earnings growth rate
100.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -12.8% |
| Return on equity | -57.3% |
| Net Margin | -71.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14
Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06
Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18Revenue & Expenses Breakdown
How Fresh Tracks Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8 | -6 | 11 | 0 |
| 30 Sep 23 | 10 | -9 | 14 | 0 |
| 30 Jun 23 | 3 | -17 | 11 | 0 |
| 31 Mar 23 | 7 | -16 | 13 | 0 |
| 31 Dec 22 | 7 | -21 | 14 | 0 |
| 30 Sep 22 | 5 | -23 | 14 | 0 |
| 30 Jun 22 | 5 | -30 | 14 | 0 |
| 31 Mar 22 | 0 | -40 | 13 | 0 |
| 31 Dec 21 | 0 | -39 | 12 | 0 |
| 30 Sep 21 | 0 | -41 | 12 | 0 |
| 30 Jun 21 | 0 | -32 | 12 | 0 |
| 31 Mar 21 | 1 | -26 | 12 | 0 |
| 31 Dec 20 | 2 | -21 | 12 | 0 |
| 30 Sep 20 | 2 | -24 | 13 | 0 |
| 30 Jun 20 | 4 | -25 | 14 | 0 |
| 31 Mar 20 | 5 | -24 | 12 | 0 |
| 31 Dec 19 | 8 | -14 | 12 | 0 |
| 30 Sep 19 | 10 | -7 | 9 | 0 |
| 30 Jun 19 | 12 | -6 | 6 | 0 |
| 31 Mar 19 | 9 | -7 | 6 | 0 |
| 31 Dec 18 | 11 | -15 | 6 | 0 |
| 31 Dec 17 | 8 | -23 | 6 | 0 |
Quality Earnings: FRTX is currently unprofitable.
Growing Profit Margin: FRTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FRTX is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare FRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: FRTX has a negative Return on Equity (-57.34%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:35 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Leland Gershell | Oppenheimer & Co. Inc. |